{
    "Rank": 1037,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00216073",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "HOG BRE03-61"
                },
                "Organization": {
                    "OrgFullName": "Hoosier Cancer Research Network",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer",
                "OfficialTitle": "A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients With HER-2 Positive Metastatic Breast Cancer: Hoosier Oncology Group BRE03-61"
            },
            "StatusModule": {
                "StatusVerifiedDate": "April 2011",
                "OverallStatus": "Terminated",
                "WhyStopped": "Lack of patient accrual",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 2004"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "October 2006",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "October 2006",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 9, 2005",
                "StudyFirstSubmitQCDate": "September 14, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 22, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "April 29, 2011",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "May 2, 2011",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Kathy Miller, M.D.",
                    "ResponsiblePartyOldOrganization": "Hoosier Oncology Group"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Hoosier Cancer Research Network",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Sanofi",
                            "CollaboratorClass": "INDUSTRY"
                        },
                        {
                            "CollaboratorName": "Hoffmann-La Roche",
                            "CollaboratorClass": "INDUSTRY"
                        },
                        {
                            "CollaboratorName": "Walther Cancer Institute",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "In vitro data suggest synergy between oxaliplatin and 5-FU. The combination of oxaliplatin with 5-fluorouracil produced objective response rates ranging from 27-34% in two studies of patients with prior chemotherapy. Capecitabine was designed as an orally administered, tumor selective fluoropyrimidine, preferentially converted to 5-FU at the tumor site by the higher levels of pyrimidine nucleoside phosphorylase (PyNPase) in tumor tissues compared to normal tissues. The end result is higher concentrations of 5-fluorouracil in tumor relative to surrounding normal tissue. Trastuzumab is synergistic in vitro with multiple chemotherapeutic agents including the platinum compounds. Studies have shown the efficacy of trastuzumab combined with chemotherapy in patients with HER2 overexpressing metastatic breast cancer. This trial will investigate the activity of capecitabine and oxaliplatin administered with trastuzumab (CAPOX-T) in patients with HER2 overexpressing in patients with advanced disease.",
                "DetailedDescription": "OUTLINE: This is a multi-center study.\n\nCAPOX-T (21 day cycle):Capecitabine 825 mg/m2 orally twice daily Days 1-14Oxaliplatin 100 mg/m2 intravenously Day 1\nTrastuzumab : 6 mg/kg intravenously Day 1.8mg/kg loading dose should be given in cycle 1 for patients without previous trastuzumab therapy only.\n\nPatients may continue combination therapy until progression or toxicity intervenes. Patients who discontinue either or both cytotoxic agents due to toxicity may, at the investigators discretion, continue therapy with the remaining agents on study until progressive disease\n\nECOG performance status 0 or 1\n\nHematopoietic:\u00b7\n\nANC > 1,200/mm3\u00b7\nPlatelets > 100,000/mm3\n\nHepatic:\u00b7\n\nTotal bilirubin < 1.5 x ULN\u00b7\nAST < 2 x ULN (up to 5 x ULN in patients with known liver involvement)\n\nRenal:\u00b7\n\nSerum creatinine < 1.5 x ULN and estimated creatinine clearance >50ml/min as calculated with Cockroft-Gault equation\n\nCardiovascular:\u00b7\n\nNo clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.\u00b7\nLVEF > LLN by MUGA or ECHO"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Metastatic Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Breast Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Non-Randomized",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "11",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "1",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Capecitabine",
                                    "Drug: Oxaliplatin",
                                    "Drug: Trastuzumab"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Capecitabine",
                            "InterventionDescription": "Capecitabine 825 mg/m2 po bid, days 1-14",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "1"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Oxaliplatin",
                            "InterventionDescription": "Oxaliplatin 100 mg/m2 IV, day 1",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "1"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Trastuzumab",
                            "InterventionDescription": "Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "1"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "- \u00b7 To determine the objective response rate (CR+PR) of capecitabine, oxaliplatin and trastuzumab(CAPOX-T) in patients with HER2 positive metastatic breast cancer.",
                            "PrimaryOutcomeTimeFrame": "18 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "To measure time to progression",
                            "SecondaryOutcomeTimeFrame": "18 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To determine rate of clinical benefit response (CR + PR + SD > 6 months)",
                            "SecondaryOutcomeTimeFrame": "18 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To determine toxicity rate of CAPOX-T in this patient population",
                            "SecondaryOutcomeTimeFrame": "18 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To explore potential correlations between changes in HER2 circulating extracellular domain in the primary tumor with response",
                            "SecondaryOutcomeTimeFrame": "18 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nHistologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease.\u00b7\nHER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry will not be sufficient for entry.\u00b7\nAt least one measurable lesion as defined by the RECIST.\nPrior hormonal therapy for metastatic disease is allowed.\nMaximum of one prior chemotherapy regimen or trastuzumab-containing regimen for unresectable, locally recurrent or metastatic disease\nPrior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease.\n\nExclusion Criteria:\n\nNo prior therapy with capecitabine or oxaliplatin in any setting\nNo prior therapy with other platinum compounds\u00b7\nNo other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to beginning protocol therapy.\u00b7\nNo prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.\u00b7\nNo prior fluoropyrimidine therapy for metastatic disease is allowed.\nPrior adjuvant fluoropyrimidine therapy is allowed if completed > 12 months from study entry.\u00b7\nNo symptomatic brain metastasis. \u00b7\nNo evidence of serious concomitant systemic disorders incompatible with the study \u00b7\nNo peripheral neuropathy \u00b7\nNo major surgery within 28 days prior to beginning protocol therapy.\u00b7\nNegative pregnancy test\u00b7\nNo current breastfeeding\u00b7\nNo malabsorption syndrome\u00b7\nNo evidence of serious concomitant systemic disorders incompatible with the study\u00b7\nPatients must not be treated with any of the following while on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol.",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Kathy Miller, M.D.",
                            "OverallOfficialAffiliation": "Hoosier Oncology Group, LLC",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Medical & Surgical Specialists, LLC",
                            "LocationCity": "Galesburg",
                            "LocationState": "Illinois",
                            "LocationZip": "61401",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Cancer Care Center of Southern Indiana",
                            "LocationCity": "Bloomington",
                            "LocationState": "Indiana",
                            "LocationZip": "47403",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Elkhart Clinic",
                            "LocationCity": "Elkhart",
                            "LocationState": "Indiana",
                            "LocationZip": "46515",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Fort Wayne Oncology & Hematology, Inc",
                            "LocationCity": "Fort Wayne",
                            "LocationState": "Indiana",
                            "LocationZip": "46815",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Indiana University Cancer Center",
                            "LocationCity": "Indianapolis",
                            "LocationState": "Indiana",
                            "LocationZip": "46202",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Quality Cancer Center (MCGOP)",
                            "LocationCity": "Indianapolis",
                            "LocationState": "Indiana",
                            "LocationZip": "46202",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Community Regional Cancer Center",
                            "LocationCity": "Indianapolis",
                            "LocationState": "Indiana",
                            "LocationZip": "46256",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Medical Consultants, P.C.",
                            "LocationCity": "Muncie",
                            "LocationState": "Indiana",
                            "LocationZip": "47303",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Northern Indiana Cancer Research Consortium",
                            "LocationCity": "South Bend",
                            "LocationState": "Indiana",
                            "LocationZip": "46601",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "AP&S Clinic",
                            "LocationCity": "Terre Haute",
                            "LocationState": "Indiana",
                            "LocationZip": "47804",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Center for Hematology/Oncology of S. Michigan",
                            "LocationCity": "Jackson",
                            "LocationState": "Michigan",
                            "LocationZip": "49201",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "SeeAlsoLinkList": {
                    "SeeAlsoLink": [
                        {
                            "SeeAlsoLinkLabel": "Hoosier Oncology Group Home Page",
                            "SeeAlsoLinkURL": "http://hoosieroncologygroup.org/"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069287",
                            "InterventionMeshTerm": "Capecitabine"
                        },
                        {
                            "InterventionMeshId": "D000077150",
                            "InterventionMeshTerm": "Oxaliplatin"
                        },
                        {
                            "InterventionMeshId": "D000068878",
                            "InterventionMeshTerm": "Trastuzumab"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000964",
                            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000000963",
                            "InterventionAncestorTerm": "Antimetabolites"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000074322",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1674",
                            "InterventionBrowseLeafName": "Oxaliplatin",
                            "InterventionBrowseLeafAsFound": "Function",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M325",
                            "InterventionBrowseLeafName": "Trastuzumab",
                            "InterventionBrowseLeafAsFound": "Via",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M377",
                            "InterventionBrowseLeafName": "Capecitabine",
                            "InterventionBrowseLeafAsFound": "Ultrasound",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M3971",
                            "InterventionBrowseLeafName": "Antimetabolites",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M1346",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}